Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04555486 · ClinicalTrials.gov registry record · Phase 1
Study to Evaluate Safety, Tolerability, PK and PD of DCR-PHXC in PH Type 3 Patients
A Phase 1 study, sponsored by Dicerna Pharmaceuticals, Inc., a Novo Nordisk company.
- Completed
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
NCT04555486 is a Phase 1 study that has completed, run by Dicerna Pharmaceuticals, Inc., a Novo Nordisk company. The registered enrollment target is 6 participants.
The verdict
NCT04555486, a Phase 1 study, has completed, sponsored by Dicerna Pharmaceuticals, Inc., a Novo Nordisk company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
The DCR-PHXC-104 study is designed to assess the safety, tolerability, and pharmacological parameters of a single dose of DCR-PHXC in Primary Hyperoxaluria Type 3 (PH3). Participants should have had at least one stone event within 12 months of screening and intact renal function.
Interventions
- DRUG Sterile Normal Saline (0.9% NaCl)
- DRUG DCR-PHXC
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2020-09-14 |
| Est. Completion | 2021-09-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04555486
The ClinicalTrials.gov registry entry for NCT04555486 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dicerna Pharmaceuticals, Inc., a Novo Nordisk company, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Sterile Normal Saline (0.9% NaCl) is the first listed.
NCT04555486 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04555486 about?
NCT04555486 is a clinical study titled "Study to Evaluate Safety, Tolerability, PK and PD of DCR-PHXC in PH Type 3 Patients". The DCR-PHXC-104 study is designed to assess the safety, tolerability, and pharmacological parameters of a single dose of DCR-PHXC in Primary Hyperoxaluria Type 3 (PH3). Participants should have had at least one stone event within 12 months of screening and intact renal function.
What is the current status of trial NCT04555486?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2020-09-14. Estimated completion is 2021-09-07.
What interventions are being tested in trial NCT04555486?
The interventions under investigation include: Sterile Normal Saline (0.9% NaCl) (DRUG), DCR-PHXC (DRUG).
Who is sponsoring clinical trial NCT04555486?
This trial is sponsored by Dicerna Pharmaceuticals, Inc., a Novo Nordisk company, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.